{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:41:16Z","timestamp":1787949676191,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["1432"],"award-info":[{"award-number":["1432"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12149-023-01839-8","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T10:03:18Z","timestamp":1682676198000},"page":"400-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The preclinical study of 177Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Sajjad","family":"Molavipordanjani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahoora","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khorramimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Talebpour Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8055-8036","authenticated-orcid":false,"given":"Seyed Jalal","family":"Hosseinimehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2007.14.8197","volume":"27","author":"G Sauter","year":"2009","unstructured":"Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323\u201333.","journal-title":"J Clin Oncol"},{"key":"1839_CR2","first-page":"141","volume":"20","author":"S Molavipordanjani","year":"2021","unstructured":"Molavipordanjani S, Hosseinimehr SJ. The Radiolabeled HER3 targeting molecules for tumor imaging. Iran J Pharm Res IJPR. 2021;20:141.","journal-title":"Iran J Pharm Res IJPR"},{"key":"1839_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fonc.2019.00754","volume":"9","author":"X Sun","year":"2019","unstructured":"Sun X, Wang S, Gai J, Guan J, Li J, Li Y, et al. SIRT5 promotes cisplatin resistance in ovarian cancer by suppressing DNA damage in a ROS-dependent manner via regulation of the Nrf2\/HO-1 pathway. Front Oncol. 2019;9:754.","journal-title":"Front Oncol"},{"key":"1839_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/cancers11050640","volume":"11","author":"J Yoo","year":"2019","unstructured":"Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers. 2019;11:640.","journal-title":"Cancers"},{"key":"1839_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.nucmedbio.2013.07.004","volume":"40","author":"K Varmira","year":"2013","unstructured":"Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors. Nucl Med Biol. 2013;40:980\u20136.","journal-title":"Nucl Med Biol"},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3109\/1061186X.2013.839688","volume":"22","author":"K Varmira","year":"2014","unstructured":"Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. J Drug Target. 2014;22:116\u201322.","journal-title":"J Drug Target"},{"key":"1839_CR7","first-page":"1523","volume":"57","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET\/CT. J Nucl Med Offil Publ Soc Nucl Med. 2016;57:1523\u20138.","journal-title":"J Nucl Med Offil Publ Soc Nucl Med"},{"key":"1839_CR8","first-page":"1340","volume":"50","author":"K McLarty","year":"2009","unstructured":"McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, et al. Micro-SPECT\/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med Offil Publ Soc Nucl Med. 2009;50:1340\u20138.","journal-title":"J Nucl Med Offil Publ Soc Nucl Med"},{"key":"1839_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7150\/thno.13502","volume":"6","author":"J S\u00f6rensen","year":"2016","unstructured":"S\u00f6rensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET\/CT. Theranostics. 2016;6:262\u201371.","journal-title":"Theranostics"},{"key":"1839_CR10","first-page":"27","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med Offil Publ Soc Nucl Med. 2016;57:27\u201333.","journal-title":"J Nucl Med Offil Publ Soc Nucl Med"},{"key":"1839_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ejmech.2018.08.029","volume":"157","author":"F Khodadust","year":"2018","unstructured":"Khodadust F, Ahmadpour S, Aligholikhamseh N, Abedi SM, Hosseinimehr SJ. Corrigendum to \u201cAn improved (99m)Tc-HYNIC-(Ser)(3)-LTVSPWY peptide with EDDA\/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor.\u201d Eur J Med Chem. 2018;157:782 (EJMECH 144, (2018) 767\u2013773).","journal-title":"Eur J Med Chem"},{"key":"1839_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104591","volume":"112","author":"J Biabani Ardakani","year":"2020","unstructured":"Biabani Ardakani J, Talebpour Amiri F, Khorramimoghaddam A, Abbasi A, Molavipordanjani S, Hosseinimehr SJ. Preclinical pharmacokinetic, biodistribution, radiation dosimetry, and toxicity studies of (99m)Tc-HYNIC-(Ser)(3)-LTVPWY: a novel HER2-targeted peptide radiotracer. Regul Toxicol Pharmacol\u202f: RTP. 2020;112: 104591.","journal-title":"Regul Toxicol Pharmacol : RTP"},{"key":"1839_CR13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/MNM.0000000000001590","volume":"43","author":"V Ranjbar","year":"2022","unstructured":"Ranjbar V, Molavipordanjani S, Biabani Ardakani J, Akhlaghi M, Nikkholgh B, Hosseinimehr SJ. Initial preclinical evaluation of 68 Ga-DOTA-(Ser) 3 -LTVSPWY peptide as a PET radiotracer for glioblastoma targeting and imaging. Nucl Med Commun. 2022;43:945\u201351.","journal-title":"Nucl Med Commun"},{"key":"1839_CR14","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.3390\/molecules27144615","volume":"27","author":"A Stringaro","year":"2022","unstructured":"Stringaro A, Serra S, Gori A, Calcabrini A, Colone M, Dupuis ML, et al. Peptide-mediated targeted delivery of Aloe-Emodin as anticancer drug. Molecules. 2022;27:4615.","journal-title":"Molecules"},{"key":"1839_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-022-01798-6","volume":"39","author":"F Ebrahimi","year":"2022","unstructured":"Ebrahimi F, Noaparast Z, Abedi SM, Hosseinimehr SJ. Homodimer 99mTc-HYNIC-E (SSSLTVPWY) 2 peptide improved HER2-overexpressed tumor targeting and imaging. Med Oncol. 2022;39:1\u201315.","journal-title":"Med Oncol"},{"key":"1839_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/09553002.2020.1704906","volume":"96","author":"S Shahsavari","year":"2020","unstructured":"Shahsavari S, Shaghaghi Z, Abedi SM, Hosseinimehr SJ. Evaluation of (99m)Tc-HYNIC-(ser)(3)-LTVPWY peptide for glioblastoma imaging. Int J Radiat Biol. 2020;96:502\u20139.","journal-title":"Int J Radiat Biol"},{"key":"1839_CR17","first-page":"862","volume":"37","author":"Z Avan","year":"2020","unstructured":"Avan Z, Biabani Ardakani J, Talebpour Amiri F, Abedi SM, Hosseinimehr SJ. The potential usefulness of (99m)Tc-HYNIC-(Ser)(3)-LTVPWY peptide for predicting HER2 status alteration after chemotherapy in ovarian tumor-bearing mice. Cancer Biother Radiopharm. 2020;37:862\u20139.","journal-title":"Cancer Biother Radiopharm"},{"key":"1839_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clbc.2022.12.002","volume":"23","author":"JB Ardakani","year":"2023","unstructured":"Ardakani JB, Abedi SM, Mardanshahi A, Shojaee L, Zaboli E, Khorramimoghaddam A, et al. Molecular imaging of HER2 expression in breast cancer patients using the [99mTc] Tc-labeled small peptide. Clin Breast Cancer. 2023;23:219\u201330.","journal-title":"Clin Breast Cancer"},{"key":"1839_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nucmedbio.2021.11.001","volume":"104","author":"V Shalgunov","year":"2022","unstructured":"Shalgunov V, Engudar G, Bohrmann L, Wharton L, Maskell K, Johann K, et al. Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225Ac, and beta-particle emitter, 177Lu. Nucl Med Biol. 2022;104:11\u201321.","journal-title":"Nucl Med Biol"},{"key":"1839_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-022-00161-4","volume":"7","author":"MSO Pijeira","year":"2022","unstructured":"Pijeira MSO, Viltres H, Kozempel J, Sakm\u00e1r M, Vlk M, \u0130lem-\u00d6zdemir D, et al. Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology. EJNMMI Radiopharm Chem. 2022;7:1\u201336.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1839_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","volume":"177","author":"G Jerusalem","year":"2019","unstructured":"Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019;177:237\u201350.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188:21\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","volume":"70","author":"GM Choong","year":"2020","unstructured":"Choong GM, Cullen GD, O\u2019Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70:355\u201374.","journal-title":"CA Cancer J Clin"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/bab.1111","volume":"60","author":"H W\u00e5llberg","year":"2013","unstructured":"W\u00e5llberg H, St\u00e5hl S. Design and evaluation of radiolabeled tracers for tumor imaging. Biotechnol Appl Biochem. 2013;60:365\u201383.","journal-title":"Biotechnol Appl Biochem"},{"key":"1839_CR25","doi-asserted-by":"publisher","first-page":"10745","DOI":"10.3390\/ijms221910745","volume":"22","author":"I Hrynchak","year":"2021","unstructured":"Hrynchak I, Santos L, Falc\u00e3o A, Gomes CM, Abrunhosa AJ. Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies. Int J Mol Sci. 2021;22:10745.","journal-title":"Int J Mol Sci"},{"key":"1839_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/ijms18020260","volume":"18","author":"SU Dalm","year":"2017","unstructured":"Dalm SU, Verzijlbergen JF, De Jong M. Review: receptor targeted nuclear imaging of breast cancer. Int J Mol Sci. 2017;18:260.","journal-title":"Int J Mol Sci"},{"key":"1839_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1021\/acs.bioconjchem.0c00617","volume":"32","author":"P Kr\u0119cisz","year":"2021","unstructured":"Kr\u0119cisz P, Czarnecka K, Kr\u00f3licki L, Mikiciuk-Olasik E, Szyma\u0144ski P. Radiolabeled peptides and antibodies in medicine. Bioconjug Chem. 2021;32:25\u201342.","journal-title":"Bioconjug Chem"},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ejmech.2016.11.011","volume":"127","author":"H Sabahnoo","year":"2017","unstructured":"Sabahnoo H, Noaparast Z, Abedi SM, Hosseinimehr SJ. New small (99m)Tc-labeled peptides for HER2 receptor imaging. Eur J Med Chem. 2017;127:1012\u201324.","journal-title":"Eur J Med Chem"},{"key":"1839_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ejmech.2017.12.037","volume":"144","author":"F Khodadust","year":"2018","unstructured":"Khodadust F, Ahmadpour S, Aligholikhamseh N, Abedi SM, Hosseinimehr SJ. An improved (99m)Tc-HYNIC-(Ser)3-LTVSPWY peptide with EDDA\/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor. Eur J Med Chem. 2018;144:767\u201373.","journal-title":"Eur J Med Chem"},{"key":"1839_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104474","volume":"106","author":"J Biabani Ardakani","year":"2021","unstructured":"Biabani Ardakani J, Akhlaghi M, Nikkholgh B, Hosseinimehr SJ. Targeting and imaging of HER2 overexpression tumor with a new peptide-based (68)Ga-PET radiotracer. Bioorg Chem. 2021;106: 104474.","journal-title":"Bioorg Chem"},{"key":"1839_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1874471008666150312160440","volume":"8","author":"JL Parus","year":"2015","unstructured":"Parus JL, Pawlak D, Mikolajczak R, Duatti A. Chemistry and bifunctional chelating agents for binding (177)Lu. Curr Radiopharm. 2015;8:86\u201394.","journal-title":"Curr Radiopharm"},{"key":"1839_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/1389200223666220113101004","volume":"23","author":"NA Gharibkandi","year":"2022","unstructured":"Gharibkandi NA, Molavipordanjani S, Mardanshahi A, Hosseinimehr SJ. The influence of kidneys ion transport inhibitors on the pharmacokinetic and tumor uptake behaviors of a HER2-targeted small size radiolabeled peptide. Curr Drug Metab. 2022;23:82\u20137.","journal-title":"Curr Drug Metab"},{"key":"1839_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12032-022-01798-6","volume":"39","author":"F Ebrahimi","year":"2022","unstructured":"Ebrahimi F, Noaparast Z, Abedi SM, Hosseinimehr SJ. Homodimer (99m)Tc-HYNIC-E(SSSLTVPWY)(2) peptide improved HER2-overexpressed tumor targeting and imaging. Med Oncol. 2022;39:204.","journal-title":"Med Oncol"},{"key":"1839_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2967\/jnumed.116.182097","volume":"58","author":"H Chen","year":"2017","unstructured":"Chen H, Jacobson O, Niu G, Weiss ID, Kiesewetter DO, Liu Y, et al. Novel \u201cAdd-On\u201d molecule based on Evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents. J Nucl Med. 2017;58:590\u20137.","journal-title":"J Nucl Med"},{"key":"1839_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.7150\/thno.14322","volume":"6","author":"H Chen","year":"2016","unstructured":"Chen H, Wang G, Lang L, Jacobson O, Kiesewetter DO, Liu Y, et al. Chemical conjugation of Evans blue derivative: a strategy to develop long-acting therapeutics through albumin binding. Theranostics. 2016;6:243\u201353.","journal-title":"Theranostics"},{"key":"1839_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.7150\/thno.24183","volume":"8","author":"EB Ehlerding","year":"2018","unstructured":"Ehlerding EB, Lan X, Cai W. \u201cAlbumin Hitchhiking\u201d with an Evans blue analog for cancer theranostics. Theranostics. 2018;8:812\u20134.","journal-title":"Theranostics"},{"key":"1839_CR37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2967\/jnumed.121.263440","volume":"63","author":"T Langbein","year":"2022","unstructured":"Langbein T, Wurzer A, Gafita A, Robertson A, Wang H, Ar\u00e7ay A, et al. The influence of specific activity on the biodistribution of (18)F-rhPSMA-7.3: a retrospective analysis of clinical PET data. J Nucl Med. 2022;63:742\u20135.","journal-title":"J Nucl Med"},{"key":"1839_CR38","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2967\/jnumed.118.223479","volume":"60","author":"F Soeda","year":"2019","unstructured":"Soeda F, Watabe T, Naka S, Liu Y, Horitsugi G, Neels OC, et al. Impact of (18)F-PSMA-1007 uptake in prostate cancer using different peptide concentrations: preclinical PET\/CT study on mice. J Nucl Med. 2019;60:1594\u20139.","journal-title":"J Nucl Med"},{"key":"1839_CR39","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1021\/acs.molpharmaceut.8b00602","volume":"15","author":"A Wurzer","year":"2018","unstructured":"Wurzer A, Pollmann J, Schmidt A, Reich D, Wester HJ, Notni J. Molar activity of Ga-68 labeled psma inhibitor conjugates determines PET imaging results. Mol Pharm. 2018;15:4296\u2013302.","journal-title":"Mol Pharm"},{"key":"1839_CR40","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.3390\/ijms22158326","volume":"22","author":"S Walrand","year":"2021","unstructured":"Walrand S, Jamar F. Renal and red marrow dosimetry in peptide receptor radionuclide therapy: 20 years of history and ahead. Int J Mol Sci. 2021;22:8326.","journal-title":"Int J Mol Sci"},{"key":"1839_CR41","doi-asserted-by":"publisher","DOI":"10.5603\/NMR.2018.0019","author":"A Kolasi\u0144ska-\u0106wik\u0142a","year":"2018","unstructured":"Kolasi\u0144ska-\u0106wik\u0142a A, \u0141owczak A, Maciejkiewicz KM, \u0106wik\u0142a JB. Peptide receptor radionuclide therapy for advanced gastroenteropancreatic neuroendocrine tumors\u2014from oncology perspective. Nucl Med Rev Cent East Eur. 2018. https:\/\/doi.org\/10.5603\/NMR.2018.0019.","journal-title":"Nucl Med Rev Cent East Eur"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-023-01839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-023-01839-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-023-01839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:19:35Z","timestamp":1687367975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-023-01839-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1007\/s12149-023-01839-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"28 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any conflict of  interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal study was approved by the Mazandaran University of Medical Sciences (ID #IR.MAZUMS.REC.1397.1432).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}